Fortrea Holdings Inc. Stock

Equities

FTRE

US34965K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
36.35 USD 0.00% Intraday chart for Fortrea Holdings Inc. +2.39% +4.15%
Sales 2024 * 3.08B Sales 2025 * 3.17B Capitalization 3.25B
Net income 2024 * -13M Net income 2025 * 88M EV / Sales 2024 * 1.38 x
Net Debt 2024 * 1B Net Debt 2025 * 842M EV / Sales 2025 * 1.29 x
P/E ratio 2024 *
-387 x
P/E ratio 2025 *
35.9 x
Employees 17,730
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.88%
More Fundamentals * Assessed data
Dynamic Chart
1 week+2.39%
Current month-9.44%
1 month-6.44%
3 months+17.56%
6 months+30.29%
Current year+4.15%
More quotes
1 week
35.13
Extreme 35.13
37.93
1 month
35.13
Extreme 35.13
40.63
Current year
29.49
Extreme 29.485
41.02
1 year
24.93
Extreme 24.925
41.02
3 years
24.93
Extreme 24.925
41.02
5 years
24.93
Extreme 24.925
41.02
10 years
24.93
Extreme 24.925
41.02
More quotes
Date Price Change Volume
24-04-26 36.35 0.00% 413,403
24-04-25 36.35 -2.42% 1,051,205
24-04-24 37.25 +0.84% 909,018
24-04-23 36.94 +4.00% 933,163
24-04-22 35.52 +0.06% 1,054,172

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes
Fortrea Holdings Inc. is a global contract research organization (CRO). The Company is providing clinical development, patient access solutions and consulting to the life sciences industry. The Company provides phase I through IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. The Company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment offers solutions to the market that include clinical pharmacology and comprehensive clinical development capabilities. Its Enabling Services segment provides patient access and technology solutions that can be deployed as a standalone offering or across its global solutions depending on the scope of its customers’ needs. The Company offers its customers with clinical trial solutions through three delivery models: Full Service, Functional Service Provider, and Hybrid.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
36.35 USD
Average target price
40.06 USD
Spread / Average Target
+10.21%
Consensus